Clinical Stage Biotech Company focused on improving the lives of systemic amyloidosis patients
Naples, FL
- Tweets 164
- Following 376
- Followers 345
- Likes 235
@Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus. Read the press release: attralus.com/press-releases/…. #amyloidosis
3
7
374
U.S. FDA grants Fast Track designation to zamubafusp alfa (AT-02) for the treatment of light chain (AL)-associated amyloidosis. Read the full announcement: attralus.com/press-releases/…
#Amyloidosis #RareDisease #ClinicalResearch
ALT Attralus announcement graphic stating that the U.S. FDA has granted Fast Track designation to zamubafusp alfa (AT-02) for the treatment of AL amyloidosis. Includes the Attralus logo and patient imagery.
2
3
285
Attralus announced FDA orphan drug designation for zamubafusp alfa (AT-02) in AL amyloidosis, a rare, progressive disease.
Read more 👉 attralus.com/press-releases/…
#Amyloidosis #ALAmyloidosis #RareDisease #OrphanDrug #FDA
ALT Graphic with Attralus logo and text announcing that zamubafusp alfa (AT‑02) received U.S. FDA orphan drug designation for AL amyloidosis, alongside a collage of patient portraits.
2
6
152
Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at #ASH2025. Read the press release: attralus.com/press-releases/… #amyloidosis
3
5
201
Attralus presents new Data on its pan-amyloid diagnostic imaging candidates at #ASNC2025. Read the press release: attralus.com/press-releases/… #amyloidosis
4
9
564
Attralus presents new data on our pan-amyloid diagnostic candidates at #ACC2025. Read the press release: attralus.com/press-releases/… #amyloidosis
1
4
8
309
Attralus announces enrollment of first patient in Phase 3 trial for the pan-amyloid diagnostic 124I-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases/….
2
7
17
5,367
Attralus receives Orphan Drug Designation from @US_FDA for AT-02 for the treatment of ATTR #amyloidosis. Read the press release: attralus.com/press-releases/…
7
15
656
Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases/….
3
9
25
4,313
Attralus receives EMA Committee for Orphan Medicinal Products positive opinions for AT-02 for treatment of both ATTR and AL #amyloidosis. Read the press release: attralus.com/press-releases/…
4
5
298
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at #ISA2024. Read the press release at attralus.com/press-releases/…. #amyloidosis
4
10
358
Looking forward to @ISA_Amyloidosis #ISA_2024 in Rochester, MN on 26-30 May. We are proud to announce 16 presentations, incl 3 oral presentations, highlighting our investigational agents and continued commitment to #amyloidosis patients. Learn more: attralus.com.
2
15
3,512
On #raredisease day we honor rare disease patients waiting for new treatments, the patient advocacy groups and healthcare providers working tirelessly to improve patients' lives, and especially the many #amyloidosis patients as they battle with this rare and devastating disease.
5
154
We are excited to announce the closing of our $56 million financing. Read more: attralus.com/press-releases/… #amyloidosis
5
117
Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging) #JACCIMG Read more - attralus.com/press-releases/… #amyloidosis
ALT Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)
9
356
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at #ASNC2023
Read more - attralus.com/press-releases/… #amyloidosis
7
13
1,115
For #NationalAmyloidosisDay, a reminder that #amyloidosis is a #raredisease that is progressive and debilitating, and as many as 80% of patients worldwide go undiagnosed or wait years to receive a diagnosis. Learn more about systemic #amyloidosis @ ow.ly/62CK50J2aZ1.
2
1
722
Attralus retweeted
New ways to target pathologic tau focus on intracellular tau, vaccines, and multivalent molecules that attack several types of fibril. #alzheimersdisease ow.ly/YgGo50Ofh39
7
26
3,461
Attralus retweeted
Attralus' experimental therapies, AT-04 and AT-07, are able to bind to proteins causing toxic clumps in Parkinson's, suggesting new treatment possibilities. buff.ly/3nSvs7V
#parkinsonsdiseaseresearch #parkinsonsdisease #livingwithparkinsons
2
8
295
Attralus retweeted
Informative video from Dr. Jonathan Wall of @attralus describing their work to develop non-invasive imaging to diagnose amyloid deposits. Great stuff.
#amyloidosis
piped.video/watch?v=7hDLbRiU…
1
6
11
660
New preclinical data on AT-04 and AT-07, our pan-amyloid removal therapeutics targeting neurodegenerative disorders was presented this past weekend at #ADPD2023. Read more attralus.com/press-releases/… #amyloidosis #AlzheimersDisease
2
3
10
775